ShuYu Civilian Pharmacy Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ShuYu Civilian Pharmacy.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Consumer Retailing earnings growth | 42.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Even With A 32% Surge, Cautious Investors Are Not Rewarding ShuYu Civilian Pharmacy Corp., Ltd.'s (SZSE:301017) Performance Completely
Nov 09
ShuYu Civilian Pharmacy (SZSE:301017) Seems To Be Using A Lot Of Debt
Oct 03A Piece Of The Puzzle Missing From ShuYu Civilian Pharmacy Corp., Ltd.'s (SZSE:301017) 25% Share Price Climb
Sep 06ShuYu Civilian Pharmacy (SZSE:301017) Could Be Struggling To Allocate Capital
Jul 25ShuYu Civilian Pharmacy Corp., Ltd. (SZSE:301017) Shares May Have Slumped 32% But Getting In Cheap Is Still Unlikely
Jun 21ShuYu Civilian Pharmacy (SZSE:301017) Use Of Debt Could Be Considered Risky
Jun 20These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt Extensively
Mar 04In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ShuYu Civilian Pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 9,735 | -42 | 96 | 248 | N/A |
| 6/30/2024 | 9,748 | 18 | -59 | 128 | N/A |
| 3/31/2024 | 9,558 | 79 | -59 | 162 | N/A |
| 12/31/2023 | 9,191 | 133 | -39 | 143 | N/A |
| 9/30/2023 | 9,110 | 261 | -86 | 110 | N/A |
| 6/30/2023 | 8,694 | 257 | -54 | 106 | N/A |
| 3/31/2023 | 8,308 | 244 | 27 | 142 | N/A |
| 1/1/2023 | 7,823 | 229 | 38 | 148 | N/A |
| 9/30/2022 | 6,854 | 135 | 148 | 237 | N/A |
| 6/30/2022 | 6,232 | 139 | 75 | 189 | N/A |
| 3/31/2022 | 5,724 | 127 | 100 | 211 | N/A |
| 1/1/2022 | 5,322 | 115 | 101 | 238 | N/A |
| 9/30/2021 | 5,018 | 203 | 75 | 234 | N/A |
| 6/30/2021 | 4,871 | 233 | 177 | 316 | N/A |
| 3/31/2021 | 4,705 | 241 | 169 | 368 | N/A |
| 12/31/2020 | 4,640 | 216 | 40 | 234 | N/A |
| 12/31/2019 | 3,467 | 111 | 8 | 123 | N/A |
| 12/31/2018 | 2,888 | 113 | -21 | 113 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 301017's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 301017's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 301017's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 301017's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 301017's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 301017's Return on Equity is forecast to be high in 3 years time